Patents Assigned to Innovative Cellular Therapeutics CO., LTD.
  • Modified Cell Expansion and Uses Thereof
    Publication number: 20190216851
    Abstract: The present disclosure relates to compositions and methods for enhancing T cell response and/or CAR cell expansion in vivo and/or in vitro. For example, a cell may comprise a first chimeric antigen receptor (CAR) and a second CAR, wherein a binding domain of the first CAR binds a first antigen, and a binding domain of the second CAR binds a second antigen. The first antigen is different from the second antigen. In embodiments, the first CAR may recognize a surface molecule of a blood cell.
    Type: Application
    Filed: September 28, 2018
    Publication date: July 18, 2019
    Applicant: Innovative Cellular Therapeutics Co., Ltd.
    Inventors: Lei Xiao, Chengfei Pu, Zhiyuan Cao, Zhao Wu
  • Chimeric antigen receptor (CAR) and T cell receptor (TCR) Modified T cells
    Publication number: 20190125798
    Abstract: The present disclosure relates to compositions and methods for compositions, methods, and kits for treating cancer using modified T cells in which TRAC genes are inactivated using a Zinc-finger nuclease (ZFN). The ZFN may include a first zinc finger protein (ZFP) that binds a first target site in a T-cell receptor alpha constant (TRAC) gene and a second ZFP that binds a second target site in the TRAC gene.
    Type: Application
    Filed: October 11, 2018
    Publication date: May 2, 2019
    Applicant: Innovative Cellular Therapeutics Co., Ltd.
    Inventors: Lei Xiao, Li Mao, Zhao Wu
  • Lymphocyte Cell Lines and Uses Thereof
    Publication number: 20190000878
    Abstract: Embodiments described herein relate to compositions including genetically modified CAR cells and uses thereof for treating cancer. Some embodiments of the present disclosure relate to compositions and methods for T cell response enhancement and/or CAR cell preparation. For example, a method may include obtaining cells comprising a CAR and culturing the cells in the presence of an agent that is recognized by the extracellular domain of the CAR.
    Type: Application
    Filed: June 29, 2018
    Publication date: January 3, 2019
    Applicant: Innovative Cellular Therapeutics Co., Ltd.
    Inventors: Lei Xiao, Chengfei Pu, Zhiyuan Cao, Zhao Wu
  • Chimeric Antigen Receptor Cell Preparation and Uses Thereof
    Publication number: 20180346876
    Abstract: Embodiments described herein relate to compositions including genetically modified CAR cells and uses thereof for treating cancer. Some embodiments of the present disclosure relate to compositions and methods for T cell response enhancement and/or CAR cell preparation. For example, a method may include obtaining cells comprising a CAR and culturing the cells in the presence of an agent that is recognized by the extracellular domain of the CAR.
    Type: Application
    Filed: May 30, 2018
    Publication date: December 6, 2018
    Applicant: Innovative Cellular Therapeutics Co., Ltd.
    Inventors: Lei Xiao, Chengfei Pu, Zhiyuan Cao, Zhao Wu
  • Activation and Expansion of T Cells
    Publication number: 20180223255
    Abstract: The present disclosure relates to compositions, methods, and systems for selectively activating and/or expanding T cells for use in therapy. For example, the method may include contacting a population of T cells with an agent capable of binding an extracellular domain of a chimeric antigen receptor (CAR) that is expressed on the surface of the population of T cells.
    Type: Application
    Filed: March 29, 2018
    Publication date: August 9, 2018
    Applicant: Innovative Cellular Therapeutics Co., Ltd.
    Inventors: Zhao Wu, Lei Xiao, Chengfei Pu
  • Use of chimeric antigen receptor modified cells to treat cancer
    Patent number: 9932405
    Abstract: The present disclosure relates to compositions and methods for compositions, methods, and kits for treating cancer using chimeric antigen receptor (CAR) modified cells. Some embodiments of the present disclosure relate to an isolated nucleic acid sequence encoding CAR. The CAR may include an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain. The antigen binding domain may bind to an antigen of a non-essential organ.
    Type: Grant
    Filed: August 24, 2017
    Date of Patent: April 3, 2018
    Assignee: Innovative Cellular Therapeutics CO., LTD.
    Inventors: Lei Xiao, Zhao Wu, Chengfei Pu, Zhiyuan Cao, He Sun, Mao Bi
  • Reducing immune tolerance induced by PD-L1
    Patent number: 9572837
    Abstract: The present disclosure relates to compositions and methods for reducing immune tolerance associated with CAR T cell therapy. Embodiments of the present disclosure include isolated nucleic acid sequence comprising a nucleic acid sequence that encodes modified programmed cell death protein 1 (PD-1) and a nucleic acid sequence that encodes chimeric antigen receptor (CAR).
    Type: Grant
    Filed: April 7, 2016
    Date of Patent: February 21, 2017
    Assignee: Innovative Cellular Therapeutics CO., LTD.
    Inventor: Zhao Wu
  • Method for directional cloning
    Patent number: 9567593
    Abstract: Described herein are techniques for directional cloning an insert DNA segments into a target vector. The techniques mix the target vector, the insert DNA segment, a restriction enzyme, and a DNA ligase to generate a recombinant DNA molecule.
    Type: Grant
    Filed: November 11, 2014
    Date of Patent: February 14, 2017
    Assignee: Innovative Cellular Therapeutics CO., LTD.
    Inventor: Zhao Wu